author-photo

Jeffrey D Bornstein

Takeda Pharmaceutical Company

3

Papers

93

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).

2021 Gastroenterology
Show All
- Source
- Cite
- Save
Citations (2)
Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn’s disease

2019 Gastroenterology
Show All
- Source
- Cite
- Save
Citations (69)
OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis

2019 Journal of Crohns & Colitis
Show All
- Source
- Cite
- Save
Citations (22)